These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20097907)

  • 21. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs.
    Scheiman JM
    Gastroenterol Clin North Am; 2009 Jun; 38(2):305-14. PubMed ID: 19446260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M; Ruschitzka F
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The unexpected side effects of new nonsteroidal anti-inflammatory drugs.
    Uzan A
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):687-8. PubMed ID: 16262557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. COX-2 inhibitors and cardiovascular risk.
    Funk CD; FitzGerald GA
    J Cardiovasc Pharmacol; 2007 Nov; 50(5):470-9. PubMed ID: 18030055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dosage on coxib- or nonsteroidal antiinflammatory drug-associated cardiovascular risk? Comment on the article by Solomon et al.
    Boers M
    Arthritis Rheum; 2007 Jan; 56(1):384; author reply 384. PubMed ID: 17195242
    [No Abstract]   [Full Text] [Related]  

  • 28. [COX-2 Inhibitors for the management of postoperative pain].
    Schug SA
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2010 Jan; 45(1):56-63. PubMed ID: 20091477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk.
    Solomon DH; Avorn J; Stürmer T; Glynn RJ; Mogun H; Schneeweiss S
    Arthritis Rheum; 2006 May; 54(5):1378-89. PubMed ID: 16645966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The practice implications of cardiovascular risks in NSAIDs.
    Hainsworth T
    Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention.
    Scarpignato C; Hunt RH
    Gastroenterol Clin North Am; 2010 Sep; 39(3):433-64. PubMed ID: 20951911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
    Kean WF; Buchanan WW
    Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selectivity of NSAIDs for COX-2 and cardiovascular outcome.
    Maxwell SR; Payne RA; Murray GD; Webb DJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):243-5. PubMed ID: 16842401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective COX-2 inhibitors: a promise unfulfilled?
    Henry D; McGettigan P
    Gastroenterology; 2007 Feb; 132(2):790-4. PubMed ID: 17261306
    [No Abstract]   [Full Text] [Related]  

  • 37. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
    Scheiman JM; Hindley CE
    Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense.
    Graham DJ
    JAMA; 2006 Oct; 296(13):1653-6. PubMed ID: 16968830
    [No Abstract]   [Full Text] [Related]  

  • 39. Cyclooxygenase-2 inhibitors and cardiovascular risk.
    Solomon SD
    Curr Opin Cardiol; 2006 Nov; 21(6):613-7. PubMed ID: 17053413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
    Dajani EZ; Islam K
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.